Group 1: Flu Season Overview - The flu season in China has entered a high incidence period, with flu-like cases in southern and northern provinces reaching 10.3% and 9.1% of total emergency visits, respectively, both higher than the previous week [1] - The demand for flu prevention and control has surged, prompting pharmaceutical companies to increase inventory and supply across all segments, including vaccines, diagnostics, treatments, and drug distribution [1] Group 2: Prevention Efforts - Hualan Biological Engineering Co., Ltd. has reported a significant increase in public awareness regarding flu vaccination, leading to a rise in demand orders from disease control centers compared to the same period last year [1] - The company has efficiently utilized its cold chain logistics to meet the vaccination needs across the country [1] Group 3: Diagnostic Solutions - Shengxiang Biotechnology Co., Ltd. has developed a rapid nucleic acid testing solution for respiratory infections, covering various pathogens and is suitable for outpatient, emergency, and inpatient settings [1] - The company has seen an increase in shipments of respiratory products since October and is well-prepared to meet the testing demand during the flu season [1] Group 4: Treatment Options - The industry is witnessing a collaborative approach in flu treatment, combining Western and traditional Chinese medicine [2] - Beijing Shuanglu Pharmaceutical Co., Ltd. has reported an increase in orders for its flu medications, including Oseltamivir and immune enhancers [2] - Hunan Fangsheng Pharmaceutical Co., Ltd. has noted a significant improvement in sales of respiratory products in the fourth quarter, although overall sales for the year still require monitoring [2] Group 5: Drug Distribution - From November, the sales of flu medications, particularly Oseltamivir and Mabalaoshuai (Sufuda), have seen significant growth at the pharmacy chain, Lao Bai Xing [3] - The company has initiated supply assurance plans ahead of the respiratory disease peak season, ensuring stable market supply through predictive measures and increased inventory [3] - The overall pharmaceutical industry is responding to the flu season by ramping up production and inventory, which not only meets public medication needs but also drives company performance [3]

双鹭药业（002038.SZ）12月2日在投资者互动平台表示，本次减持已结束，限售股为高管锁定股，每年 年初重新以持股数量25%计算解除锁定。 每经AI快讯，有投资者在投资者互动平台提问：剩下的限售股什么时候可以上市流通？什么时候继续 减持？ （文章来源：每日经济新闻） ...

证券日报网讯12月2日，双鹭药业（002038）在互动平台回答投资者提问时表示，公司会在定期报告中 披露股东人数变化，截至2025年9月30日，公司股东总户数为54779户。 ...

证券日报网讯12月2日，双鹭药业（002038）在互动平台回答投资者提问时表示，公司始终高度重视信 息披露工作，严格遵守上市规则，所有公告均依法依规进行。 ...

Core Viewpoint - The company has a range of antiviral and immune-enhancing products in its portfolio, including those for influenza treatment and prevention, as well as innovative drugs in development [1] Group 1: Current Products - The company offers Oseltamivir and Clindamycin as antiviral medications for influenza [1] - Immune-enhancing agents in the company's product line include Thymosin Alpha 1 and Interleukin-2 [1] Group 2: Innovative Drug Development - The company is developing innovative drugs such as Long-acting Follicle Stimulating Hormone and DT-678 [1]

格隆汇12月2日丨双鹭药业(002038.SZ)在投资者互动平台表示，公司除奥司他韦外还有克林霉素等产 品，此外还有提升免疫力的胸腺五肽、白介素-2等免疫增强剂，目前开发的创新药有长效促卵泡激素、 DT-678等。 ...

格隆汇12月2日丨双鹭药业(002038.SZ)在投资者互动平台表示，目前奥司他韦订单数量有所增加，其与 其他抗流感类药物的具体销售情况公司也在密切关注。 ...

格隆汇12月2日丨双鹭药业(002038.SZ)在投资者互动平台表示，目前奥司他韦订单数量有所增加，其与 其他抗流感类药物的具体销售情况公司也在密切关注。 ...

Core Viewpoint - The company, Shuanglu Pharmaceutical, emphasizes the advantages of its exclusive nitroglycerin spray, which is designed for emergency treatment of angina and is included in the national medical insurance directory [1] Group 1: Product Advantages - The nitroglycerin spray is more convenient to use, acts faster, and has a higher safety profile compared to traditional forms [1] - The product can be absorbed directly through the oral mucosa without the need for dissolution, typically taking effect within 30 seconds to 1 minute [1] Group 2: Market Context - There has been a rising incidence of sudden cardiac death and myocardial infarction, particularly among younger individuals, attributed to high stress, irregular diet, and lifestyle [1] - The nitroglycerin spray is positioned as a household emergency medication for patients with angina [1] Group 3: Marketing Strategy - The company is increasing its promotional efforts and strengthening collaborations with various pharmaceutical sales channels to enhance market coverage [1] - The goal is for the nitroglycerin spray to become a key product for the company in the future [1]

Group 1: Impact of National Drug Procurement - The company has been significantly affected by the 8th and 9th batches of national drug procurement, with major products entering procurement and experiencing price reductions of up to 70% [2][3] - Temozolomide capsules saw a price drop of 62% during the 4th batch procurement, yet sales revenue increased by 109% despite the price cut [5][6] - The average price of several biological products decreased by approximately 15% due to regional alliance procurement [3] Group 2: Business Model and Product Structure - The company operates as a biopharmaceutical enterprise, covering drug research, production, and marketing, with a focus on expanding into the health sector [4] - The product structure has shifted from a high reliance on major products to a more diversified portfolio, enhancing risk resistance [6][11] - Oral solid preparations now account for over 50% of the product mix, reflecting a significant change from previous years when injectables dominated [12] Group 3: New Product Launches and Profit Contribution - The contribution of new and upcoming products to profits depends on their procurement success and market expansion of non-procurement products [6] - The company has a rich pipeline of new products, indicating a potential shift towards a multi-product profit model [6] Group 4: Production Capacity and Operations - The company has eight major production bases, with some operating at full capacity and others reserved for future product launches [7] - Plans are in place to transfer some production to lower-cost locations to participate in larger-scale procurement [7] Group 5: Sales Performance and Key Products - The top ten products by sales revenue in the first three quarters of 2025 include: - Fuzhifu: 59.6 million CNY - Temozolomide capsules: 55.2 million CNY - Oseltamivir phosphate capsules: 52.7 million CNY [8] - Changes in invoicing models have affected reported sales revenue, complicating the assessment of actual sales performance [8] Group 6: International Investments and Collaborations - The company holds a 30% stake in Diapin Therapeutics, focusing on innovative drug development for diabetes and cardiovascular diseases [9] - ATGC Company is developing a unique therapeutic antibody platform using genetically modified rabbits, with significant progress reported [10] Group 7: Market Position and Stock Performance - The company has faced a prolonged adjustment period due to policy changes and competitive pressures, with market capitalization remaining below 10 billion CNY for years [13] - Management emphasizes the importance of developing competitive products to improve performance and shareholder returns [13] Group 8: Recent Investments - The company invested 10 million CNY in Changfeng Pharmaceutical, which is now publicly listed, holding a 3.68% stake valued at nearly 500 million CNY [15] - The investment in Xuan Bamboo Biotechnology also resulted in a public listing, with a 0.34% stake valued at approximately 206 million CNY [15]